AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Akari Therapeutics, Plc
Video analysis: AKTX
All videosNo video analysis for this stock yet. Request one from our team.
News: AKTX
Akari Therapeutics (NASDAQ:AKTX) Stock Crosses Above Fifty Day Moving Average – Should You Sell?
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $9.65 and traded as high as $12.04. Akari Therapeutics shares last traded at $10.96, with a volume of 128,527 shares. Wall Street Analyst Weigh In Several
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available here
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company's recently announced strategic research collaboration with WhiteHawk Therapeutics and why the Company believes scientifically driven collaborations will play an increasingly important role in advancing the next generation of ADC innovation.
Akari Therapeutics (NASDAQ:AKTX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $9.24 and traded as low as $7.19. Akari Therapeutics shares last traded at $7.36, with a volume of 24,072 shares traded. Wall Street Analysts Forecast Growth
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform
